Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Hypertension US FDA label
Kidney dosing: Amlodipine (single-agent)Show full dosing details
- eGFR ≥60
- Usual dosing: 5 mg once daily, maximum 10 mg (label).
- eGFR 30–59
- No adjustment (label).
- eGFR 15–29
- No adjustment (label).
- eGFR <15 (not on dialysis)
- Usual initial dose (label: patients with renal failure).
- Hemodialysis (intermittent)
- No adjustment; hemodialysis is unlikely to remove amlodipine (label, Overdosage).
- Peritoneal dialysis
- No label adjustment; no PD data (amlodipine is hepatically cleared and not dialyzed).
- CRRT
- No data in label.
- Dialyzable? No: highly protein bound; hemodialysis not likely to help (label).
- Monitoring Blood pressure, edema. Lower starting dose (2.5 mg) in older adults and hepatic impairment (label).
From the Amlodipine monograph (renalcarematters.com, reviewed).
Use: As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated US FDA label
Kidney dosing: Atorvastatin (single-agent)Show full dosing details
- eGFR ≥60
- No adjustment (label).
- eGFR 30–59
- No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
- eGFR 15–29
- No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
- eGFR <15 (not on dialysis)
- No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
- Hemodialysis (intermittent)
- No dose adjustment (not dialyzed; label). KDIGO: do not start a statin in most patients already on dialysis; continue if already taking one at dialysis initiation.
- Peritoneal dialysis
- No label adjustment; no PD data.
- CRRT
- No data in label.
- Dialyzable? Not expected to be significantly removed by hemodialysis (label).
- Monitoring Muscle symptoms (myopathy, rhabdomyolysis); renal impairment is a risk factor (label).
From the Atorvastatin monograph (renalcarematters.com, reviewed).
Use: Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Film-coated tablet: 10 mg/5 mg/5 mg, 20 mg/5 mg/5 mg, 40 mg/10 mg/10 mg
Registered products in the Philippines
3 products registered with the Food and Drug Administration (FDA) Philippines list Amlodipine + Atorvastatin + Perindopril as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products3
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
TriveramAtorvastatin (as calcium) + Perindopril (as arginine) + Amlodipine (as besilate) | 20 mg/5 mg/5 mg Film-Coated TabletPolypropylene bottle equipped with a Low-Density Polyethylene flow reducer and a Low-Density Polyethylene stopper x 30's (Box of 1's) | RxVAT-exempt | Les Laboratories Servier IndustrieFrance | Zuellig Pharma CorporationImporter: Servier Philippines, Inc. | DR-XY46377 | Apr 22, 2031 | |
Triveram ForteAtorvastatin (as calcium) + Perindopril (as arginine) + Amlodipine (as besilate) | 40 mg/10 mg/10 mg Film-Coated TabletPolypropylene bottle equipped with a Low-Density Polyethylene flow reducer and a Low-Density Polyethylene stopper x 30's (Box of 1's) | RxVAT-exempt | Les Laboratories Servier IndustrieFrance | Zuellig Pharma CorporationImporter: Servier Philippines, Inc. | DR-XY46374 | Apr 22, 2031 | |
Triveram InitioAtorvastatin (as calcium) + Perindopril (as arginine) + Amlodipine (as besilate) | 10 mg/5 mg/5 mg Film-coated TabletPolypropylene bottle equipped with a Low-Density Polyethylene flow reducer and a Low-Density Polyethylene stopper x 30's (Box of 1's) | RxVAT-exempt | Les Laboratories Servier IndustrieFrance | Zuellig Pharma CorporationImporter: Servier Philippines, Inc. | DR-XY46378 | Apr 22, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .